Note: [01 Mar 2017] – The following is a consolidation of 13-501F1. It incorporates amendments to this document that came into effect on March 1, 2017. This consolidation is provided for your convenience and should not be relied on as authoritative.

FORM 13-501F1 CLASS 1 REPORTING ISSUERS AND CLASS 3B REPORTING ISSUERS – PARTICIPATION FEE

MANAGEMENT CERTIFICATION

Τ

Γ

I, Jacqueline Tucker , an officer of Form 13-501F1 (the Form) being subm certify that to my knowledge, having ex the Form is complete and accurate.	itted hereunder to th	e Alberta Securit	ties Com	mission and
/s/ lacqueline Tucker		May 1 0	022	
/s/ Jacqueline Tucker Name: Jacqueline Tucker	Date:	May 1, 2	.025	
Title: CFO	Dute.			
Reporting Issuer Name:	ASEP Medical Ho	ldings Inc.		
1 9				
End date of previous financial year:	December 31, 2022			
Turne of Deneuting Lagran			ang 2D .	
Type of Reporting Issuer:	[×] Class 1 reporting [] Class 3B reporting issuer issuer			
	Issuel	155001		
	Considion Convritio			
Highest Trading Marketplace: Canadian Securities Exchange				
Market value of listed or quoted equip	ty securities:			
Equity Symbol		ASEP		_
1st Specified Trading Period (dd/mm/	vv)	01/01/22	to	31/03/22
]]]	01/01/22		51,05,22
Closing price of the security in the class				
last trading day of the specified trading such security was listed or quoted on the	1	¢		0.4466
marketplace	c mgnest traumg	• (i)		0.4100
		(1)		

Number of securities in the class or series of such security outstanding at the end of the last trading day the specified trading period	of	(ii)		56,130,344
Market value of class or series	(i) x (ii)	\$(A)		23,013,441.04
2nd Specified Trading Period (dd/mm/yy)		01/04/22	to	30/06/22
Closing price of the security in the class or series on last trading day of the specified trading period in whi such security was listed or quoted on the highest trad marketplace	ch	\$ (iii)		0.3400
Number of securities in the class or series of such security outstanding at the end of the last trading day the specified trading period	of	(iv)		56,130,344
Market value of class or series	(iii) x (iv	7) \$ (B)		19,084,316.96
3rd Specified Trading Period (dd/mm/yy)		01/07/22	to	30/09/22
Closing price of the security in the class or series on last trading day of the specified trading period in whi such security was listed or quoted on the highest trad marketplace	ch	\$(v)		0.1950
Number of securities in the class or series of such security outstanding at the end of the last trading day the specified trading period	of	(vi)		56,130,344
Market value of class or series	(v) x (vi))		10,945,417.08

4th Specified Trading Period (dd/mm/yy)	01,	/10/22	_ to	31/12/22
Closing price of the security in the class or series on th last trading day of the specified trading period in which such security was listed or quoted on the highest tradin marketplace	1	\$(vii)		0.6400
Number of securities in the class or series of such security outstanding at the end of the last trading day o the specified trading period	f	(viii)		62,130,344
Market value of class or series	(vii) x (viii)	\$ (D)		39,763,420.16
5th Specified Trading Period (dd/mm/yy)			_ to	
Closing price of the security in the class or series on th last trading day of the specified trading period in which such security was listed or quoted on the highest tradin marketplace	1	\$ (ix)		
Number of securities in the class or series of such security outstanding at the end of the last trading day o the specified trading period	f	(x)		
Market value of class or series	(ix) x (x)	\$ (E)		
Average Market Value of Class or Series (Calculate the simple average of the market value of the class or series of security for each applicable specified trading period (i.e. A through E above))		\$ (1)		23,201,648.81

(Repeat the above calculation for each other class or series of equity securities of the reporting issuer (and a subsidiary, if applicable) that was listed or quoted on a marketplace at the end of the previous financial year)

Fair value of outstanding debt securities:

(Provide details of how value was determined)		\$(2)	0.0000
Capitalization for the previous financial year	(1) + (2)	\$	23,201,648.81
Participation Fee		\$	500.0000
Late Fee, if applicable		\$	
Total Fee Payable (Participation Fee plus Late Fee)		\$	500.0000